{"protocolSection":{"identificationModule":{"nctId":"NCT02289833","orgStudyIdInfo":{"id":"BO29389"},"secondaryIdInfos":[{"id":"2014-001237-83","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Phase 2, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received At Least One Prior Chemotherapy Regimen"},"statusModule":{"statusVerifiedDate":"2019-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-12-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-10-25","type":"ACTUAL"},"completionDateStruct":{"date":"2018-08-20","type":"ACTUAL"},"studyFirstSubmitDate":"2014-11-04","studyFirstSubmitQcDate":"2014-11-10","studyFirstPostDateStruct":{"date":"2014-11-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-10-24","resultsFirstSubmitQcDate":"2017-10-24","resultsFirstPostDateStruct":{"date":"2017-11-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-07-23","lastUpdatePostDateStruct":{"date":"2019-08-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 2, multicenter study designed to evaluate the efficacy and safety of trastuzumab emtansine administered as a single-agent in participants with HER2-positive (HER2 IHC 2+ or HER2 IHC 3+) advanced or metastatic NSCLC. Participants will be treated with trastuzumab emtansine administered intravenously at a dose of 3.6 milligrams per kilogram (mg/kg) on Day 1 of 21-day cycles until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor, whichever occurs first."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":49,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort IHC2+","type":"EXPERIMENTAL","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.","interventionNames":["Drug: Trastuzumab Emtansine"]},{"label":"Cohort IHC3+","type":"EXPERIMENTAL","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.","interventionNames":["Drug: Trastuzumab Emtansine"]}],"interventions":[{"type":"DRUG","name":"Trastuzumab Emtansine","description":"Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.","armGroupLabels":["Cohort IHC2+","Cohort IHC3+"],"otherNames":["Kadcyla, T-DM1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Objective Response as Per Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v. 1.1)","description":"Objective response is defined as a complete response (CR) or partial response (PR) determined on two consecutive assessments ≥ 4 weeks apart, based on investigator assessment according to RECIST, Version 1.1. CR: disappearance of all target lesions; and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 millimeters (mm). PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.","timeFrame":"From Day 1 to disease progression (PD) or death from any cause, up to the clinical cutoff date (approximately 22 months)"}],"secondaryOutcomes":[{"measure":"Percentage of Participants Who Died","timeFrame":"From Day 1 to death from any cause, up to the study completion date (approximately 43 months)"},{"measure":"Overall Survival (OS)","description":"OS is defined as the time from first study drug administration to death from any cause.","timeFrame":"From Day 1 to death from any cause, up to the study completion date (approximately 43 months)"},{"measure":"Percentage of Participants With PFS Event of Disease Progression, as Per Investigator Assessment According to RECIST v. 1.1, or Death","description":"PFS is defined as the time from first study drug administration to first documented disease progression, based on investigator assessment using RECIST, v1.1, or death from any cause during the study, whichever occurs first. Disease progression is defined as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions.","timeFrame":"From Day 1 to PD or death from any cause, up to the study completion date (approximately 43 months)"},{"measure":"Progression-Free Survival (PFS) as Per Investigator Assessment According to RECIST v. 1.1","description":"PFS is defined as the time from first study drug administration to first documented disease progression, based on investigator assessment using RECIST, v1.1, or death from any cause during the study, whichever occurs first. Disease progression is defined as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions.","timeFrame":"From Day 1 to PD or death from any cause, up to the study completion date (approximately 43 months)"},{"measure":"Percentage of Participants With DOR Event of Disease Progression, Assessed According to RECIST v1.1","description":"DOR is defined as the time from the initial documentation of response (CR or PR using RECIST, v1.1) to documented disease progression using RECIST v1.1 or death from any cause during the study. CR: disappearance of all target lesions; and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions.","timeFrame":"From first documented objective response to PD or death from any cause, up to the study completion date (approximately 43 months)"},{"measure":"Duration of Objective Response (DOR) Assessed According to RECIST v1.1","description":"DoR is defined as the time from the initial documentation of response (CR or PR using RECIST, v1.1) to documented disease progression using RECIST v1.1 or death from any cause during the study. CR: disappearance of all target lesions; and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions.","timeFrame":"From first documented objective response to PD or death from any cause, up to the study completion date (approximately 43 months)"},{"measure":"Percentage of Participants With Clinical Benefit as Per Investigator Assessment According to RECIST, v1.1","description":"Clinical benefit is defined as having a CR or PR or stable disease (using RECIST, v1.1) at 6 months. Participants with no post-baseline response assessment are considered as experiencing no clinical benefit. CR: disappearance of all target lesions; and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum while in the study. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions.","timeFrame":"From Day 1 to PD or death from any cause, up to the study completion date (approximately 43 months)"},{"measure":"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, whether or not considered related to the study drug. A SAE is any experience that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.","timeFrame":"From Day 1 to 30 days after last dose of study drug, up to the study completion date (approximately 43 months)"},{"measure":"Maximum Observed Concentration (Cmax) for Trastuzumab Emtansine and Total Trastuzumab","description":"Cmax is the 0-21 day maximum observed concentration of a drug and was measured in blood serum.","timeFrame":"Pre-dose (within 2 days) and 30 minutes (min) after end of infusion (infusion length= 100 min or less) on Day 1 of Cycles 1 and 3 (one cycle=21 days); at treatment discontinuation/early termination, up to primary analysis, approx. 22 months"},{"measure":"AUCinf for Trastuzumab Emtansine and Total Trastuzumab","description":"AUC (from zero to infinity) represents the total drug exposure over time in blood serum.","timeFrame":"Pre-dose & 30 minutes (min) post-infusion (inf.) on Day (D) 1 of Cycles (C) 1 & 3; post- inf. on D 2, 3, 4 or 5, 8, & 15 of C 1, & pre- inf. on D1 of C2 & D1 of C 4 (C=21 D); at discontin./termination, up to primary analysis, approx. 22 months"},{"measure":"Elimination Half-Life (t1/2) for Trastuzumab Emtansine and Total Trastuzumab","description":"t1/2 is the time required for the drug serum concentration to be reduced to half.","timeFrame":"Pre-dose & 30 minutes (min) post-infusion (inf.) on D 1 of C 1 & 3; post- inf. on D 2, 3, 4 or 5, 8, & 15 of C 1, & pre- inf. on D 1 of C 2 & D 1 of C 4 (C=21 days); at treatment discontin./early termination, up to primary analysis, approx. 22 months"},{"measure":"Volume of Distribution (Vss) for Trastuzumab Emtansine and Total Trastuzumab","description":"Vss is the volume of distribution of study drug at steady state.","timeFrame":"Pre-dose & 30 minutes (min) post-infusion (inf.) on D1 of C1 & 3; post- inf. on D2, 3, 4 or 5, 8, & 15 of C 1, & pre- inf. on D 1 of C 2 & D1 of C 4 (C=21 days); at treatment discontin/early termination, up to primary analysis, approx. 22 months"},{"measure":"Clearance (CL) for Trastuzumab Emtansine and Total Trastuzumab","description":"CL is a measure of the body's elimination of a drug from blood serum over time.","timeFrame":"Pre-dose & 30 minutes (min) post-infusion (inf.) on D 1 of C 1 & 3; post- inf. on D 2, 3, 4 or 5, 8, & 15 of C 1, & pre- inf. on D 1 of C 2 & D 1 of C 4 (C=21 days); at treatment discontin/early termination, up to primary analysis, approx. 22 months"},{"measure":"Maximum Observed Concentration (Cmax) for N2'- Deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maytansine (DM1)","description":"Cmax is the maximum observed concentration of a drug and was measured in blood plasma.","timeFrame":"Pre-dose (within 2 days) and 30 minutes (min) after end of infusion (infusion length= 100 min or less) on Day 1 of Cycle 1 (one cycle=21 days); at treatment discontinuation/early termination,up to primary analysis, approx. 22 months"},{"measure":"Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs)","description":"The presence of ADAs in blood serum is an indication of the body's immune response to a drug.","timeFrame":"Pre-dose (within 2 days) on Day 1 of Cycles 1 and 3; at treatment discontinuation/early termination,up to primary analysis, approx. 22 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically documented diagnosis of Stage IIIB not amenable to radical treatment or Stage IV NSCLC (pathological characterization must determine the non-squamous or squamous histological subtype as well as adenocarcinoma subtype classification)\n* HER2 status of IHC 2+ or 3+ as determined by a Sponsor-designated central laboratory\n* Prior treatment with at least one regimen of platinum-based (cisplatin or carboplatin) chemotherapy in the locally advanced or metastatic setting/recurrent NSCLC with documented disease progression by investigator assessment\n* Participants with a known anaplastic lymphoma kinase (ALK) fusion oncogene (must be documented in the participant's chart) must have also experienced disease progression or intolerance with a first-line ALK Tyrosine Kinase Inhibitor (TKI) approved for the treatment of ALK fusion oncogene NSCLC (for example, crizotinib). Disease progression or intolerance must be documented\n* Participants with a known mutation in the epidermal growth factor receptor (EGFR) gene (must be documented in the participant's chart) must have also experienced disease progression or intolerance with an EGFR TKI approved for the treatment of EGFR-mutant NSCLC (for example, gefitinib, erlotinib, afatinib). Disease progression or intolerance must be documented\n* Measurable disease determined as per the RECIST v1.1\n* Life expectancy of at least (\\>/=) 12 weeks\n* Adequate organ function\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Left ventricular ejection fraction (LVEF) \\>/= 50 percent (%) by either echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan\n* Use of highly effective contraception\n\nExclusion Criteria:\n\nCancer-Related Criteria:\n\n* Any approved anti-cancer therapy less than or equal to (\\</=) 21 days (including chemotherapy or hormonal therapy) before the first study treatment; the following exceptions are allowed: (1) TKIs approved for the treatment of NSCLC must be discontinued greater than (\\>) 7 days prior to the first study treatment on D1C1 (The baseline computed tomography \\[CT\\] scan must be completed after discontinuation of TKIs); (2) Hormone-replacement therapy or oral contraceptives; (3) Anti-emetics, Granulocyte-colony stimulating factor (GCS-F), and prophylactic antibiotics according to local standards\n* Investigational therapy participation in another clinical study with therapeutic intent \\</= 21 days before first study treatment\n* Previous irradiation is permitted if \\>/=14 days since the last fraction of radiotherapy have elapsed before the first study treatment on Day 1 as long as a sufficient number of target lesions remain to allow for measurable disease as per RECIST v1.1\n* Participants who have untreated brain metastases or are symptomatic; participants with treated brain metastases must have discontinued corticosteroid therapy and not have any neurological symptoms\n* History of intolerance (including Grade 3 or 4 infusion reaction) or hypersensitivity to trastuzumab or murine proteins or any excipient of the product\n* History of exposure to the following cumulative doses of anthracyclines: Doxorubicin or liposomal doxorubicin \\> 500 milligram per meter-square (mg/m\\^2); Epirubicin \\> 900 mg/m\\^2; Mitoxantrone \\> 120 mg/m\\^2. If another anthracycline, or more than one anthracycline, has been used, the cumulative dose must not exceed the equivalent of 500 mg/m\\^2 doxorubicin\n* Peripheral neuropathy of Grade \\>/= 3 per the National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE v. 4.0)\n* History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those mentioned above\n\nCardiopulmonary Function Criteria:\n\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Severe dyspnea at rest due to complications of advanced malignancy or requiring current continuous oxygen therapy\n* Clinical history of active hemoptysis\n* Evidence of active pneumonitis during screening\n* Current unstable ventricular arrhythmia requiring treatment\n* History of symptomatic congestive heart failure (CHF) New York Heart Association (NYHA) classes II-IV\n* History of myocardial infarction or unstable angina within 6 months of enrollment\n* History of a decrease in LVEF to \\<50%\n\nGeneral Criteria:\n\n* Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)\n* Major surgical procedure or significant traumatic injury within 28 days before enrollment or anticipation of the need for major surgery during the course of study treatment\n* Current pregnancy or lactation\n* Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Rush University Medical Center","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Karmanos Cancer Institute","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"University of North Carolina at Chapel Hill","city":"Chapel Hill","state":"North Carolina","zip":"27514","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Seattle Cancer Care Alliance","city":"Seattle","state":"Washington","zip":"98109","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"HELIOS Klinikum Emil von Behring Klinik f.Pneumologie Onkologie u.Infektiologie","city":"Berlin","zip":"14165","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Kaiserswerther Diakonie Florence Nightingale-Krankenh. Tagesklinik f.Onkologie","city":"Düsseldorf","zip":"40489","country":"Germany","geoPoint":{"lat":51.22172,"lon":6.77616}},{"facility":"Asklepios-Fachkliniken Muenchen-Gauting; Onkologie","city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II","city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"Fachklinik für Lungenerkrankungen","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"Azienda Ospedaliera Univ Parma; Dept Oncologia Medica","city":"Parma","state":"Emilia-Romagna","zip":"43100","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"facility":"Istituto Europeo Di Oncologia","city":"Milan","state":"Lombardy","zip":"20141","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Medical University of Gdansk","city":"Gdansk","zip":"80-211","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii","city":"Otwock","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Seoul National University Hospital","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center - Oncology","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital Univ Vall d'Hebron; Servicio de Oncologia","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Ramon y Cajal; Servicio de Oncologia","city":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario La Paz; Servicio de Oncologia","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"CHUV; Departement d'Oncologie","city":"Lausanne","zip":"1011","country":"Switzerland","geoPoint":{"lat":46.516,"lon":6.63282}},{"facility":"UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie","city":"Zurich","zip":"8091","country":"Switzerland","geoPoint":{"lat":47.36667,"lon":8.55}}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Subjects were screened centrally for HER2 status, using archived tumor specimens from previously collected tissue, if available.","groups":[{"id":"FG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"FG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"17"}]}],"dropWithdraws":[{"type":"Study discontinuation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"16"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"BG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"49"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.1","spread":"10.3"},{"groupId":"BG001","value":"61.4","spread":"8.6"},{"groupId":"BG002","value":"62.4","spread":"9.6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"20"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"29"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Objective Response as Per Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v. 1.1)","description":"Objective response is defined as a complete response (CR) or partial response (PR) determined on two consecutive assessments ≥ 4 weeks apart, based on investigator assessment according to RECIST, Version 1.1. CR: disappearance of all target lesions; and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 millimeters (mm). PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.","populationDescription":"The efficacy-evaluable population included participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From Day 1 to disease progression (PD) or death from any cause, up to the clinical cutoff date (approximately 22 months)","groups":[{"id":"OG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"OG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","lowerLimit":"0","upperLimit":"11.9"},{"groupId":"OG001","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Died","populationDescription":"The efficacy-evaluable population included participants who received at least one dose of study drug. Data are reported for participants with events.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Day 1 to death from any cause, up to the study completion date (approximately 43 months)","groups":[{"id":"OG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"OG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3"},{"groupId":"OG001","value":"80.0"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from first study drug administration to death from any cause.","populationDescription":"The efficacy-evaluable population included participants who received at least one dose of study drug. Data are reported for participants with events.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From Day 1 to death from any cause, up to the study completion date (approximately 43 months)","groups":[{"id":"OG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"OG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","lowerLimit":"3.8","upperLimit":"23.6"},{"groupId":"OG001","value":"13.7","lowerLimit":"4.1","upperLimit":"33.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With PFS Event of Disease Progression, as Per Investigator Assessment According to RECIST v. 1.1, or Death","description":"PFS is defined as the time from first study drug administration to first documented disease progression, based on investigator assessment using RECIST, v1.1, or death from any cause during the study, whichever occurs first. Disease progression is defined as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions.","populationDescription":"The efficacy-evaluable population included participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Day 1 to PD or death from any cause, up to the study completion date (approximately 43 months)","groups":[{"id":"OG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"OG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"95.0"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) as Per Investigator Assessment According to RECIST v. 1.1","description":"PFS is defined as the time from first study drug administration to first documented disease progression, based on investigator assessment using RECIST, v1.1, or death from any cause during the study, whichever occurs first. Disease progression is defined as: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions.","populationDescription":"The efficacy-evaluable population included participants who received at least one dose of study drug. Data are reported for participants with events.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From Day 1 to PD or death from any cause, up to the study completion date (approximately 43 months)","groups":[{"id":"OG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"OG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"1.4","upperLimit":"2.8"},{"groupId":"OG001","value":"2.7","lowerLimit":"1.4","upperLimit":"8.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With DOR Event of Disease Progression, Assessed According to RECIST v1.1","description":"DOR is defined as the time from the initial documentation of response (CR or PR using RECIST, v1.1) to documented disease progression using RECIST v1.1 or death from any cause during the study. CR: disappearance of all target lesions; and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions.","populationDescription":"The efficacy-evaluable population included participants who received at least one dose of study drug. Data are reported for participants with response.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From first documented objective response to PD or death from any cause, up to the study completion date (approximately 43 months)","groups":[{"id":"OG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"OG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"75.0","lowerLimit":"2.9","upperLimit":"8.3"}]}]}]},{"type":"SECONDARY","title":"Duration of Objective Response (DOR) Assessed According to RECIST v1.1","description":"DoR is defined as the time from the initial documentation of response (CR or PR using RECIST, v1.1) to documented disease progression using RECIST v1.1 or death from any cause during the study. CR: disappearance of all target lesions; and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions.","populationDescription":"The efficacy-evaluable population included participants who received at least one dose of study drug. Data are reported for participants with response.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From first documented objective response to PD or death from any cause, up to the study completion date (approximately 43 months)","groups":[{"id":"OG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"OG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"7.3","lowerLimit":"2.9","upperLimit":"NA","comment":"The upper limit confidence interval was not calculable due to the low number of participants with events."}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Benefit as Per Investigator Assessment According to RECIST, v1.1","description":"Clinical benefit is defined as having a CR or PR or stable disease (using RECIST, v1.1) at 6 months. Participants with no post-baseline response assessment are considered as experiencing no clinical benefit. CR: disappearance of all target lesions; and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum while in the study. Disease progression: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions.","populationDescription":"The efficacy-evaluable population included participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From Day 1 to PD or death from any cause, up to the study completion date (approximately 43 months)","groups":[{"id":"OG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"OG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","lowerLimit":"0.85","upperLimit":"22.77"},{"groupId":"OG001","value":"30.0","lowerLimit":"11.89","upperLimit":"54.28"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)","description":"An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, whether or not considered related to the study drug. A SAE is any experience that: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.","populationDescription":"The safety-evaluable population included participants who received at least one dose of study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Day 1 to 30 days after last dose of study drug, up to the study completion date (approximately 43 months)","groups":[{"id":"OG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."},{"id":"OG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"20"}]}],"classes":[{"title":"AEs","categories":[{"measurements":[{"groupId":"OG000","value":"93.1"},{"groupId":"OG001","value":"95.0"}]}]},{"title":"SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"17.2"},{"groupId":"OG001","value":"25.0"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Concentration (Cmax) for Trastuzumab Emtansine and Total Trastuzumab","description":"Cmax is the 0-21 day maximum observed concentration of a drug and was measured in blood serum.","populationDescription":"The pharmacokinetic (PK) population included participants who had received at least one dose of study treatment and had at least one serum or plasma concentration result available at clinical data cut-off. Data are reported for evaluable participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"micrograms per milliliter (ug/mL)","timeFrame":"Pre-dose (within 2 days) and 30 minutes (min) after end of infusion (infusion length= 100 min or less) on Day 1 of Cycles 1 and 3 (one cycle=21 days); at treatment discontinuation/early termination, up to primary analysis, approx. 22 months","groups":[{"id":"OG000","title":"Pharmacokinetic (PK) Analysis Group","description":"Participants with HER2 IHC2 or IHC3-positive (IHC 2+ or IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"}]}],"classes":[{"title":"Trastuzumab Emtansine","categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":"19.6"}]}]},{"title":"Total Trastuzumab","categories":[{"measurements":[{"groupId":"OG000","value":"79.9","spread":"21.3"}]}]}]},{"type":"SECONDARY","title":"AUCinf for Trastuzumab Emtansine and Total Trastuzumab","description":"AUC (from zero to infinity) represents the total drug exposure over time in blood serum.","populationDescription":"The pharmacokinetic (PK) population included participants who had received at least one dose of study treatment and had at least one serum or plasma concentration result available at clinical data cut-off. Data are reported for evaluable participants who consented to intense sampling.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days times ug/mL (day* ug/mL)","timeFrame":"Pre-dose & 30 minutes (min) post-infusion (inf.) on Day (D) 1 of Cycles (C) 1 & 3; post- inf. on D 2, 3, 4 or 5, 8, & 15 of C 1, & pre- inf. on D1 of C2 & D1 of C 4 (C=21 D); at discontin./termination, up to primary analysis, approx. 22 months","groups":[{"id":"OG000","title":"Pharmacokinetic (PK) Analysis Group","description":"Participants with HER2 IHC2 or IHC3-positive (IHC 2+ or IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"title":"Trastuzumab Emtansine","categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":"49.9"}]}]},{"title":"Total Trastuzumab","categories":[{"measurements":[{"groupId":"OG000","value":"436","spread":"83.4"}]}]}]},{"type":"SECONDARY","title":"Elimination Half-Life (t1/2) for Trastuzumab Emtansine and Total Trastuzumab","description":"t1/2 is the time required for the drug serum concentration to be reduced to half.","populationDescription":"The pharmacokinetic (PK) population included participants who had received at least one dose of study treatment and had at least one serum or plasma concentration result available at clinical data cut-off. Data are reported for evaluable participants who consented to intense sampling.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days","timeFrame":"Pre-dose & 30 minutes (min) post-infusion (inf.) on D 1 of C 1 & 3; post- inf. on D 2, 3, 4 or 5, 8, & 15 of C 1, & pre- inf. on D 1 of C 2 & D 1 of C 4 (C=21 days); at treatment discontin./early termination, up to primary analysis, approx. 22 months","groups":[{"id":"OG000","title":"Pharmacokinetic (PK) Analysis Group","description":"Participants with HER2 IHC2 or IHC3-positive (IHC 2+ or IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"title":"Trastuzumab Emtansine","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"0.51"}]}]},{"title":"Total Trastuzumab","categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"Volume of Distribution (Vss) for Trastuzumab Emtansine and Total Trastuzumab","description":"Vss is the volume of distribution of study drug at steady state.","populationDescription":"The pharmacokinetic (PK) population included participants who had received at least one dose of study treatment and had at least one serum or plasma concentration result available at clinical data cut-off. Data are reported for evaluable participants who consented to intense sampling.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"milliliters kilogram (mL/kg)","timeFrame":"Pre-dose & 30 minutes (min) post-infusion (inf.) on D1 of C1 & 3; post- inf. on D2, 3, 4 or 5, 8, & 15 of C 1, & pre- inf. on D 1 of C 2 & D1 of C 4 (C=21 days); at treatment discontin/early termination, up to primary analysis, approx. 22 months","groups":[{"id":"OG000","title":"Pharmacokinetic (PK) Analysis Group","description":"Participants with HER2 IHC2 or IHC3-positive (IHC 2+ or IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"title":"Trastuzumab Emtansine","categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":"1.81"}]}]},{"title":"Total Trastuzumab","categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":"4.23"}]}]}]},{"type":"SECONDARY","title":"Clearance (CL) for Trastuzumab Emtansine and Total Trastuzumab","description":"CL is a measure of the body's elimination of a drug from blood serum over time.","populationDescription":"The pharmacokinetic (PK) population included participants who had received at least one dose of study treatment and had at least one serum or plasma concentration result available at clinical data cut-off. Data are reported for evaluable participants who consented to intense sampling.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mL/day/kg","timeFrame":"Pre-dose & 30 minutes (min) post-infusion (inf.) on D 1 of C 1 & 3; post- inf. on D 2, 3, 4 or 5, 8, & 15 of C 1, & pre- inf. on D 1 of C 2 & D 1 of C 4 (C=21 days); at treatment discontin/early termination, up to primary analysis, approx. 22 months","groups":[{"id":"OG000","title":"Pharmacokinetic (PK) Analysis Group","description":"Participants with HER2 IHC2 or IHC3-positive (IHC 2+ or IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"classes":[{"title":"Trastuzumab Emtansine","categories":[{"measurements":[{"groupId":"OG000","value":"11.35","spread":"1.99"}]}]},{"title":"Total Trastuzumab","categories":[{"measurements":[{"groupId":"OG000","value":"8.54","spread":"1.99"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Concentration (Cmax) for N2'- Deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maytansine (DM1)","description":"Cmax is the maximum observed concentration of a drug and was measured in blood plasma.","populationDescription":"The pharmacokinetic (PK) population included participants who had received at least one dose of study treatment and had at least one serum or plasma concentration result available at clinical data cut-off. Data are reported for evaluable participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanograms per milliliter (ng/mL)","timeFrame":"Pre-dose (within 2 days) and 30 minutes (min) after end of infusion (infusion length= 100 min or less) on Day 1 of Cycle 1 (one cycle=21 days); at treatment discontinuation/early termination,up to primary analysis, approx. 22 months","groups":[{"id":"OG000","title":"Pharmacokinetic (PK) Analysis Group","description":"Participants with HER2 IHC2 or IHC3-positive (IHC 2+ or IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"3.36"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs)","description":"The presence of ADAs in blood serum is an indication of the body's immune response to a drug.","populationDescription":"The pharmacokinetic (PK) population included participants who had received at least one dose of study treatment and had at least one serum or plasma concentration result available at clinical data cut-off. Data are reported for evaluable participants with post-dose sample available for ADA analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Pre-dose (within 2 days) on Day 1 of Cycles 1 and 3; at treatment discontinuation/early termination,up to primary analysis, approx. 22 months","groups":[{"id":"OG000","title":"Anti-drug Antibody Analysis Group","description":"Participants with HER2 IHC2 or IHC3-positive (IHC 2+ or IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From baseline to study completion (approximately 43 months)","eventGroups":[{"id":"EG000","title":"Cohort IHC2+","description":"Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.","deathsNumAffected":23,"deathsNumAtRisk":29,"seriousNumAffected":5,"seriousNumAtRisk":29,"otherNumAffected":24,"otherNumAtRisk":29},{"id":"EG001","title":"Cohort IHC3+","description":"Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.","deathsNumAffected":16,"deathsNumAtRisk":20,"seriousNumAffected":5,"seriousNumAtRisk":20,"otherNumAffected":19,"otherNumAtRisk":20}],"seriousEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]}],"otherEvents":[{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":29},{"groupId":"EG001","numAffected":3,"numAtRisk":20}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":29},{"groupId":"EG001","numAffected":4,"numAtRisk":20}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":4,"numAtRisk":20}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":29},{"groupId":"EG001","numAffected":3,"numAtRisk":20}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":29},{"groupId":"EG001","numAffected":3,"numAtRisk":20}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":4,"numAtRisk":20}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Pulmonary pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":29},{"groupId":"EG001","numAffected":3,"numAtRisk":20}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":29},{"groupId":"EG001","numAffected":3,"numAtRisk":20}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":3,"numAtRisk":20}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":29},{"groupId":"EG001","numAffected":4,"numAtRisk":20}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":3,"numAtRisk":20}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":3,"numAtRisk":20}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Petechiae","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":29},{"groupId":"EG001","numAffected":4,"numAtRisk":20}]},{"term":"Skin Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":29},{"groupId":"EG001","numAffected":0,"numAtRisk":20}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":2,"numAtRisk":20}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":3,"numAtRisk":20}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Depressive symptom","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":3,"numAtRisk":20}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Metrorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Vaginal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Poor venous access","organSystem":"Vascular disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Mucosal Dryness","organSystem":"General disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Viral Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Iron Deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Bone Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Pain in Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Oropharyngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]},{"term":"Onychoclasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDra, Version 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29},{"groupId":"EG001","numAffected":1,"numAtRisk":20}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-LaRoche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000080044","term":"Ado-Trastuzumab Emtansine"}],"ancestors":[{"id":"D008453","term":"Maytansine"},{"id":"D018942","term":"Macrolides"},{"id":"D007783","term":"Lactones"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D047029","term":"Lactams, Macrocyclic"},{"id":"D047028","term":"Macrocyclic Compounds"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D000068878","term":"Trastuzumab"},{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}